依奇珠单抗治疗中重度斑块状银屑病60周的药代动力学、抗药抗体与疗效
本研究基于一项随机对照3期试验,分析依奇珠单抗治疗中重度斑块状银屑病60周期间血清药物浓度、治疗中出现抗药抗体(TE-ADA)与疗效的关系。起始剂量160mg后每2周80mg,第12周迅速达到稳态谷浓度并伴高临床应答;长期扩展期每4周80mg维持稳定谷浓度至第60周。82.6%(308/373)患者从未产生TE-ADA,多数患者TE-ADA对血药浓度和疗效影响可忽略。
要点
- 起始160mg后每2周80mg,第12周迅速达稳态谷浓度并伴高临床应答。
- 长期扩展期每4周80mg维持稳定谷浓度,高临床应答维持至第60周。
- 82.6%(308/373)患者从未产生TE-ADA,多数患者TE-ADA对浓度和疗效影响可忽略。
核心结论
- 对多数患者而言,治疗中出现抗药抗体对依奇珠单抗血清浓度和疗效的影响可忽略。
研究设计与样本
- 随机对照3期研究,分析依奇珠单抗治疗中重度斑块状银屑病60周期间药代动力学、抗药抗体与疗效的关系。
主要发现
- 起始剂量160mg后每2周80mg,第12周迅速达到稳态谷浓度并伴高临床应答。
- 长期扩展期每4周80mg,稳定谷浓度维持高临床应答至第60周。
- 82.6%(308/373)患者从未产生TE-ADA;17.4%(n=65)为TE-ADA阳性,其滴度、中和能力及持续性存在差异。
- 56例(15%)患者最大滴度为低或中等,其血清浓度和疗效与TE-ADA阴性患者相当。
- 9例(2.4%)患者出现高滴度,个体临床应答不一,其中4例在第60周至少达到PASI 75。
关键数值与推荐
- TE-ADA高滴度组的中位血清浓度与较低滴度组的中位血清浓度总体相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A, is efficacious for moderate to severe plaque psoriasis. We examined relationships between serum ixekizumab concentrations, treatment-emergent anti-drug antibodies (TE-ADAs), and efficacy during 60 weeks of treatment in a randomized, controlled, phase 3 study. Steady-state ixekizumab serum trough concentrations were rapidly achieved and associated with high clinical responses at week 12 with a starting dose of 160 mg followed by 80 mg every 2 weeks. During the long-term extension period dosage of 80 mg every 4 weeks, stable serum trough concentrations maintained high clinical responses through week 60. Most (82.6%, 308/373) patients never developed TE-ADA. In TE-ADA-positive patients (17.4%, n = 65), variations in ADA titers, neutralizing capacity, and persistence were observed. Fifty-six patients (15%) developed low or moderate maximum titers, with serum concentrations and efficacy comparable to those of TE-ADA-negative patients. Nine patients (2.4%) developed high titers, with variable individual clinical responses; four of these nine patients achieved at least PASI 75 at week 60. Median serum concentrations in the TE-ADA-high titer group were generally comparable to the median serum concentrations in the lower titer groups. For most patients, TE-ADA had a negligible impact on ixekizumab serum concentrations and efficacy. Clinicaltrials.gov: NCT01646177.
引用
- Reich K, Jackson K, Ball S, et al. Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. J Invest Dermatol. 2018. PMID: 29751001. doi:10.1016/j.jid.2018.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。